硼替佐米联合来那度胺和地塞米松对比单用来那度胺和地塞米松治疗不适合立即自体干细胞移植的新诊断骨髓瘤患者(SWOG S0777):一项随机、开放标签、3期试验
该随机开放标签3期试验纳入525例不适合立即自体干细胞移植的新诊断多发性骨髓瘤患者,比较硼替佐米联合来那度胺和地塞米松(VRd组)与来那度胺和地塞米松(Rd组)。VRd组中位无进展生存期43个月 vs Rd组30个月(分层HR 0.712,96%CI 0.56-0.906,单侧P=0.0018),中位总生存期75个月 vs 64个月(HR 0.709,95%CI 0.524-0.959,双侧P=0.025),均显著改善。
要点
- VRd组中位无进展生存期43个月,显著优于Rd组30个月(HR 0.712,96%CI 0.56-0.906,单侧P=0.0018)。
- VRd组中位总生存期75个月,显著优于Rd组64个月(HR 0.709,95%CI 0.524-0.959,双侧P=0.025)。
- VRd组3级及以上不良事件发生率82%(198/241),高于Rd组75%(169/226);因不良事件终止诱导治疗者分别为23%(55例)和10%(22例)。
核心结论
- 在新诊断骨髓瘤患者中,在来那度胺和地塞米松基础上加用硼替佐米可显著改善无进展生存期和总生存期,且具有可接受的风险-获益特征。
研究设计与样本
- 随机、开放标签、3期试验,于2008年4月至2012年2月从参与的西南肿瘤协作组(SWOG)和国家临床试验网络(NCTN)机构(含住院和门诊)招募525例新诊断多发性骨髓瘤患者,按1:1随机分配至VRd组(264例)或Rd组(261例),按国际分期系统分期和是否计划移植分层,分析采用意向性治疗原则。
主要发现
- VRd组中位无进展生存期43个月 vs Rd组30个月(分层HR 0.712,96%CI 0.56-0.906;单侧P=0.0018)。
- VRd组中位总生存期75个月 vs Rd组64个月(HR 0.709,95%CI 0.524-0.959;双侧P=0.025)。
- 可评估缓解的患者中,VRd组总缓解率(部分缓解或更好)82%(176/216) vs Rd组72%(153/214);完全缓解或更好分别为16%(34/216) vs 8%(18/214)。
- 3级及以上不良事件:VRd组198/241(82%) vs Rd组169/226(75%);因不良事件终止诱导治疗:VRd组55例(23%) vs Rd组22例(10%)。
- 治疗相关死亡:Rd组无,VRd组2例。
关键数值与推荐
- VRd方案:8个21天周期,硼替佐米1.3 mg/m²静脉注射,第1、4、8、11天;来那度胺25 mg口服每日,第1-14天;地塞米松20 mg口服每日,第1、2、4、5、8、9、11、12天。
- Rd方案:6个28天周期,来那度胺25 mg口服每日,第1-21天;地塞米松40 mg口服每日,第1、8、15、22天。
- 主要终点为无进展生存期,采用预设单侧分层对数秩检验,显著性水平0.02。
临床怎么用
- 对于不适合立即自体干细胞移植的新诊断多发性骨髓瘤患者,可考虑硼替佐米联合来那度胺和地塞米松方案(作者结论认为该方案显著改善生存且风险-获益可接受)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant. METHODS: In this randomised, open-label, phase 3 trial, we recruited patients with newly diagnosed multiple myeloma aged 18 years and older from participating Southwest Oncology Group (SWOG) and National Clinical Trial Network (NCTN) institutions (both inpatient and outpatient settings). Key inclusion criteria were presence of CRAB (C=calcium elevation; R=renal impairment; A=anaemia; B=bone involvement) criteria with measurable disease (measured by assessment of free light chains), Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, haemoglobin concentration 9 g/dL or higher, absolute neutrophil count 1 × 103 cells per mm3 or higher, and a platelet count of 80 000/mm3 or higher. We randomly assigned (1:1) patients to receive either an initial treatment of bortezomib with lenalidomide and dexamethasone (VRd group) or lenalidomide and dexamethasone alone (Rd group). Randomisation was stratified based on International Staging System stage (I, II, or III) and intent to transplant (yes vs no). The VRd regimen was given as eight 21-day cycles. Bortezomib was given at 1·3 mg/m2 intravenously on days 1, 4, 8, and 11, combined with oral lenalidomide 25 mg daily on days 1-14 plus oral dexamethasone 20 mg daily on days 1, 2, 4, 5, 8, 9, 11, and 12. The Rd regimen was given as six 28-day cycles. The standard Rd regimen consisted of 25 mg oral lenalidomide once a day for days 1-21 plus 40 mg oral dexamethasone once a day on days 1, 8, 15, and 22. The primary endpoint was progression-free survival using a prespecified one-sided stratified log rank test at a significance level of 0·02. Analyses were intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00644228. FINDINGS: Between April, 2008, and February, 2012, we randomly assigned 525 patients at 139 participating institutions (264 to VRd and 261 to Rd). In the randomly assigned patients, 21 patients in the VRd group and 31 in the Rd group were deemed ineligible based mainly on missing, insufficient, or early or late baseline laboratory data. Median progression-free survival was significantly improved in the VRd group (43 months vs 30 months in the Rd group; stratified hazard ratio [HR] 0·712, 96% CI 0·56-0·906; one-sided p value 0·0018). The median overall survival was also significantly improved in the VRd group (75 months vs 64 months in the Rd group, HR 0·709, 95% CI 0·524-0·959; two-sided p value 0·025). The rates of overall response (partial response or better) were 82% (176/216) in the VRd group and 72% (153/214) in the Rd group, and 16% (34/216) and 8% (18/214) of patients who were assessable for response in these respective groups had a complete response or better. Adverse events of grade 3 or higher were reported in 198 (82%) of 241 patients in the VRd group and 169 (75%) of 226 patients in the Rd group; 55 (23%) and 22 (10%) patients discontinued induction treatment because of adverse events, respectively. There were no treatment-related deaths in the Rd group, and two in the VRd group. INTERPRETATION: In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progression-free and overall survival and had an acceptable risk-benefit profile. FUNDING: NIH, NCI, NCTN, Millennium Pharmaceuticals, Takeda Oncology Company, and Celgene Corporation.
引用
- Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2016. PMID: 28017406. doi:10.1016/S0140-6736(16)31594-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。